Skip to main content

Advertisement

SpringerLink
Log in

Analysis of the expression of angiotensin II type 1 receptor and VEGF in endometrial adenocarcinoma with different clinicopathological characteristics

  • Research Article
  • Published:
Tumor Biology

Abstract

In Poland, endometrial carcinoma takes second place after breast cancer among all cancers in women and is considered the most common genital cancer. It has been repeatedly reported that angiotensin is involved in the development and invasion of some cancers including breast, ovarian, and pancreatic ones. It is suggested that angiotensin two and its receptors are actively involved in tumour biology in endometrial adenocarcinoma. In the present study, we identify a possible relationship between the expression of AT1-R, AT2-R, ERα, and VEGF and clinicopathological characteristics of primary endometrial adenocarcinoma. We determined the above components both at the mRNA (real-time RT-PCR) and protein levels (Western Blot assay). Our results indicate that in patients with grade G3 adenocarcinoma, the expression of AT1-R significantly decreased in comparison with G1 patients (p = 0.034), but the level of ERα was the highest in G2 and the lowest in G3. Moreover, the level of VEGF mRNA significantly increased between G2 and G3 (p = 0.034). We also noted a significant correlation between the expression of AT1-R and AT2-R in FIGO stage 1 (R s = 0.9636; p = 0.0001) and that of AT2-R and VEGF (R s = 0.5377; p = 0.005). In grade G1 and G2 carcinoma, a significant correlation was also found between the expression of AT1-R and AT2-R (R s = 0.9924; p = 0.0001; R s = 0.8717, p = 0.0005, respectively), but in grade G1, a negative correlation was observed between AT1-R and VEGF (R s = −0.8945, p = 0.0005). Further studies are required to clarify the biological function of the angiotensin receptor in regulating VEGF expression in endometrial carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Grosman-Dziewiszek P, Dziegiel P, Zabel M. Disturbance of gene expression in endometrial cancer as therapy aim. Ginekol Pol. 2011;82:276–80.

    PubMed  Google Scholar 

  2. Shibata K, Kikkawa F, Mizokami Y, Kajiyama H, Ino K, Nomura S, Mizutani S. Possible involvement of adipocyte-derived leucine aminopeptidase via angiotensin II in endometrial carcinoma. Tumour Biol. 2005;26:9–16.

    Article  PubMed  CAS  Google Scholar 

  3. Lam KY, Leung PS. Regulation and expression of a renin–angiotensin system in human pancreas and pancreatic endocrine tumours. Eur J Endocrinol. 2002;146:567–72.

    Article  PubMed  CAS  Google Scholar 

  4. Uemura H, Ishiguro H, Nagashima Y, Sasaki T, Nakaigawa N, Hasumi H, Kato S, Kubota Y. Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells. Mol Cancer Ther. 2005;4:1699–709.

    Article  PubMed  CAS  Google Scholar 

  5. Ager EI, Neo J, Christophi C. The renin–angiotensin system and malignancy. Carcinogenesis. 2008;29:1675–84.

    Article  PubMed  CAS  Google Scholar 

  6. Day RT, Cavaglieri RC, Tabatabaimir H, Mantravadi V, Lee MJ, Barnes JL, Kasinath BS, Feliers D. Acute hyperglycemia rapidly stimulates VEGF mRNA translation in the kidney. Role of angiotensin type 2 receptor (AT2). Cell Signal. 2010;22:1849–57.

    Article  PubMed  CAS  Google Scholar 

  7. Hsueh WA. Renin in the female reproductive system. Cardiovasc Drugs Ther. 1988;2:473–7.

    Article  PubMed  CAS  Google Scholar 

  8. Mitchell MD, Edwin SS, Pollard JK, Trautman MS. Renin stimulates decidual prostaglandin production via a novel mechanism that is independent of angiotensin II formation. Placenta. 1996;17:299–305.

    Article  PubMed  CAS  Google Scholar 

  9. Watanabe Y, Shibata K, Kikkawa F, Kajiyama H, Ino K, Hattori A, Tsujimoto M, Mizutani S. Adipocyte-derived leucine aminopeptidase suppresses angiogenesis in human endometrial carcinoma via renin–angiotensin system. Clin Cancer Res. 2003;9:6497–503.

    PubMed  CAS  Google Scholar 

  10. Giatromanolaki A, Sivridis E, Brekken R, Thorpe PE, Anastasiadis P, Gatter KC, Harris AL, Koukourakis MI. The angiogenic “vascular endothelial growth factor/flk-1(KDR) receptor” pathway in patients with endometrial carcinoma: prognostic and therapeutic implications. Cancer. 2001;92:2569–77.

    Article  PubMed  CAS  Google Scholar 

  11. Taylor SE, Patel II, Singh PB, Nicholson CM, Stringfellow HF, Gopala Krishna RK, Matanhelia SS, Martin-Hirsch PL, Martin FL. Elevated oestrogen receptor splice variant ERalphaDelta5 expression in tumour-adjacent hormone-responsive tissue. Int J Environ Res Publ Health. 2010;7:3871–89.

    Article  CAS  Google Scholar 

  12. Sivridis E, Giatromanolaki A, Koukourakis M, Anastasiadis P. Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression. Virchows Arch. 2001;438:470–7.

    Article  PubMed  CAS  Google Scholar 

  13. Ryan AJ, Susil B, Jobling TW, Oehler MK. Endometrial cancer. Cell Tissue Res. 2005;322:53–61.

    Article  PubMed  Google Scholar 

  14. Vandesompele J, De PK, Pattyn F, Poppe B, Van RN, De PA, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:RESEARCH0034.

    Google Scholar 

  15. de Kok JB, Roelofs RW, Giesendorf BA, Pennings JL, Waas ET, Feuth T, Swinkels DW, Span PN. Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest. 2005;85:154–9.

    PubMed  Google Scholar 

  16. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002;30:e36.

    Article  PubMed  Google Scholar 

  17. Neo JH, Ager EI, Angus PW, Zhu J, Herath CB, Christophi C. Changes in the renin angiotensin system during the development of colorectal cancer liver metastases. BMC Cancer. 2010;10:134.

    Article  PubMed  Google Scholar 

  18. Schauser KH, Nielsen AH, Dantzer V, Poulsen K. Angiotensin-converting enzyme activity in the bovine uteroplacental unit changes in relation to the cycle and pregnancy. Placenta. 2001;22:852–62.

    Article  PubMed  CAS  Google Scholar 

  19. Ino K, Shibata K, Yamamoto E, Kajiyama H, Nawa A, Mabuchi Y, Yagi S, Minami S, Kikkawa F. 2011 Role of the renin-angiotensin system in gynecologic cancers. Curr Cancer Drug Targets 11(4):405-11

    Google Scholar 

  20. Tahmasebi M, Barker S, Puddefoot JR, Vinson GP. Localisation of renin–angiotensin system (RAS) components in breast. Br J Cancer. 2006;95:67–74.

    Article  PubMed  CAS  Google Scholar 

  21. Lau ST, Leung PS (2011). Role of the RAS in pancreatic cancer. Curr Cancer Drug Targets 11(4):412-20

    Google Scholar 

  22. Koh SL, Ager EI, Christophi C. Liver regeneration and tumour stimulation: implications of the renin–angiotensin system. Liver Int. 2010;30:1414–26.

    Article  PubMed  CAS  Google Scholar 

  23. Bai X, Mi R. Expression of VEGF, bFGF and ER in endometrial carcinoma. Zhonghua Zhong Liu Za Zhi. 2001;23:211–3.

    PubMed  CAS  Google Scholar 

  24. Yasue A, Hasegawa K, Udagawa Y (2011). Effects of tamoxifen on the endometrium and its mechanism of carcinogenicity. Hum Cell 24(2):65-73

    Google Scholar 

Download references

Acknowledgments

The authors acknowledge Medical University of Lodz Contract grant number: 503/0-078-04/502-19-581 and 503/0-078-04/503-01.

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Comparative Endocrinology, Medical University of Lodz, Lodz, Poland

    Agnieszka Wanda Piastowska-Ciesielska & Tomasz Ochędalski

  2. Department of Molecular Carcinogenesis, Medical University of Lodz, Lodz, Poland

    Elżbieta Płuciennik & Andrzej Bednarek

  3. Clinical Division of Gynecological Oncology, Medical University of Lodz, Lodz, Poland

    Katarzyna Wójcik-Krowiranda & Andrzej Bieńkiewicz

  4. Department of Comparative Endocrinology, Faculty of Biomedical Sciences and Postgraduate Training, Medical University of Lodz, Zeligowskiego 7/9, Lodz, 90-752, Poland

    Agnieszka Wanda Piastowska-Ciesielska

Authors
  1. Agnieszka Wanda Piastowska-Ciesielska
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elżbieta Płuciennik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katarzyna Wójcik-Krowiranda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrzej Bieńkiewicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andrzej Bednarek
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tomasz Ochędalski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Agnieszka Wanda Piastowska-Ciesielska.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Piastowska-Ciesielska, A.W., Płuciennik, E., Wójcik-Krowiranda, K. et al. Analysis of the expression of angiotensin II type 1 receptor and VEGF in endometrial adenocarcinoma with different clinicopathological characteristics. Tumor Biol. 33, 767–774 (2012). https://doi.org/10.1007/s13277-011-0292-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-011-0292-0

Keywords

Search

Navigation